Drug Profile


Alternative Names: ISIS-306053; OGX-427

Latest Information Update: 25 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of British Columbia
  • Developer OncoGenex Pharmaceuticals; Queen Mary Medical School; Sarah Cannon Research Institute
  • Class Antineoplastics; Antisense oligonucleotides
  • Mechanism of Action HSP27 heat shock protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Bladder cancer

Highest Development Phases

  • Phase II Non-small cell lung cancer; Pancreatic cancer; Prostate cancer
  • Suspended Bladder cancer
  • Discontinued Breast cancer; Ovarian cancer

Most Recent Events

  • 01 Oct 2017 Hoosier Cancer Research Network completes the phase II Borealis-2 trial for Bladder cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (IV) (NCT01780545)
  • 21 Jun 2017 Hoosier Cancer Research Network terminates a phase II trial in Prostate Cancer (Combination therapy, Metastatic disease) in USA and Canada due to lack of accrual (NCT01681433)
  • 05 May 2017 Sarah Cannon Research Institute and OncoGenex Pharmaceuticals completes the phase II Spruce™ trial for Non-small cell lung cancer (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in USA (NCT01829113)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top